Comparative Pharmacology
Head-to-head clinical analysis: FELDENE versus MOBIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELDENE versus MOBIC.
FELDENE vs MOBIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
20 mg orally once daily, or 10 mg orally twice daily. Maximum daily dose: 20 mg.
7.5-15 mg orally once daily. Maximum 15 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 30-86 hours), allowing once-daily dosing. The long half-life results from enterohepatic recirculation.
Terminal elimination half-life: ~20 hours (range 13–20 h); allows once-daily dosing; prolonged in elderly (25–26 h) and hepatic impairment.
Approximately 60-70% of a dose is excreted in urine as unchanged drug and metabolites, with about 30-40% eliminated in feces via biliary secretion.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~50% via feces; enterohepatic recirculation occurs.
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug
Nonsteroidal Anti-Inflammatory Drug